Abstract
AbstractThe COVID-19 pandemic forced industry and national regulatory authorities (NRAs) to think about innovative ways to ensure business continuity, including Good Manufacturing Practices (GMP) inspections. Even prior to COVID-19, it was understood that GMP site inspections, especially redundant inspections, are a time and resource-intensive process for both industry and regulators in high-income countries and often prohibitive to resource-challenged countries. Thus, we investigated the use of a mixed reality device and Microsoft (MS) Teams as a platform for mixed reality (hybrid) remote inspection. This pilot involved a mock GMP inspection of a drug manufacturing facility in the United States. The mock inspection was conducted by two former USFDA (US Food and Drug Administration) investigators, facilitated by representatives from Northeastern University along with The Bill and Melinda Gates Foundation. Also participating in the inspection were inspectors from national regulatory agencies (NRAs) from the African continent, including Nigeria, South Africa, Uganda, and Zimbabwe, and representatives from the Pre-Qualification Inspection Unit at the World Health Organization (WHO). Harmonized inspectional guidance from PIC/s (GMP Guide) and WHO (TRS 823) were used as the standards for conducting the mock inspection. We found that mixed reality, used in conjunction with a collaborative text messaging system, is a viable tool to facilitate remote inspections and allows inspectors participating remotely to write their own independent inspection reports.
Funder
Bill and Melinda Gates Foundation
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Public Health, Environmental and Occupational Health,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference13 articles.
1. cGMP in Manufacturing, Processing, Packaging, or Holding of Drugs and Finished Pharmaceuticals. 2021.
2. Yu LX, Woodcock J. FDA pharmaceutical quality oversight. Int J Pharm. 2015;491(1–2):2–7.
3. A New World for Pharmaceutical Inspections The Mutal Recognition Agreement. US FDA Foreign GMP Inspection; 2023.
4. Tirivangani T, Alpo B, Kibuule D, Gaeseb J, Adenuga BA. Impact of COVID-19 pandemic on pharmaceutical systems and supply chain—a phenomenological study. Explor Res Clin Soc Pharm. 2021;2: 100037.
5. Information Sharing. 2018. https://www.fda.gov/federal-state-local-tribal-and-territorial-officials/communications-outreach/information-sharing
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献